Iol Chemicals Pharmaceuticals Ltd vs Solara Active Pharma Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of IOL Chemicals & Pharmaceuticals Ltd is ₹ 94.66 as of 05 May 15:30 . The P/E Ratio of IOL Chemicals & Pharmaceuticals Ltd changed from 12.4 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Solara Active Pharma Sciences Ltd changed from 3943 on March 2025 to 22.6 on March 2021 . This represents a CAGR of -92.43% over 2 years The Market Cap of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 2077 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Solara Active Pharma Sciences Ltd changed from ₹ 2394 crore on March 2022 to ₹ 5009 crore on March 2021 . This represents a CAGR of 15.91% over 5 years The revenue of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 585.68 crore as compare to the Sep '25 revenue of ₹ 574.41 crore. This represent the growth of 1.96% The revenue of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 349 crore as compare to the Sep '25 revenue of ₹ 314.03 crore. This represent the growth of 11.14% The ebitda of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 51.36 crore as compare to the Sep '25 ebitda of ₹ 63.96 crore. This represent the decline of -19.7% The ebitda of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 30.59 crore as compare to the Sep '25 ebitda of ₹ 35.22 crore. This represent the decline of -13.15% The net profit of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 29.97 crore to ₹ 20.58 crore over 7 quarters. This represents a CAGR of -19.33% The net profit of Solara Active Pharma Sciences Ltd changed from ₹ -13.46 crore to ₹ -17.43 crore over 7 quarters. This represents a CAGR of 15.92% The Dividend Payout of IOL Chemicals & Pharmaceuticals Ltd changed from 7.92 % on March 2021 to 23.25 % on March 2025 . This represents a CAGR of 24.03% over 5 yearsThe Dividend Payout of Solara Active Pharma Sciences Ltd changed from 11.38 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors.
Its extensive expertise in both API and specialty chemicals strengthens the business model and opens doors to diversified growth opportunities. Within the API segment, IOL develops and supplies a wide range of essential products utilized by pharmaceutical companies worldwide for the production of key medicines.
It serves as a global supplier of various APIs, including Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, and Fenofibrate, alongside other APIs, and maintains a significant presence in all major therapeutic categories. In the Specialty Chemicals division, IOL manufactures Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA), and Acetyl Chloride.

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs).
The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru. The Company offer rich basket of niche high-value products for global markets.
The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others.
These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.

FAQs for the comparison of IOL Chemicals & Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd

Which company has a larger market capitalization, IOL Chemicals & Pharmaceuticals Ltd or Solara Active Pharma Sciences Ltd?

Market cap of IOL Chemicals & Pharmaceuticals Ltd is 2,778 Cr while Market cap of Solara Active Pharma Sciences Ltd is 1,815 Cr

What are the key factors driving the stock performance of IOL Chemicals & Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd?

The stock performance of IOL Chemicals & Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for IOL Chemicals & Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd?

As of May 5, 2026, the IOL Chemicals & Pharmaceuticals Ltd stock price is INR ₹94.66. On the other hand, Solara Active Pharma Sciences Ltd stock price is INR ₹501.8.

How do dividend payouts of IOL Chemicals & Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd compare?

To compare the dividend payouts of IOL Chemicals & Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.